Affibody AB’s License and Collaboration Agreement with ACELYRIN, INC.

Wiggin and Dana represented Affibody AB on the deal.

Affibody AB signed a partnership agreement with ACELYRIN, INC. to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases. Under the terms of the agreement, Affibody will receive a USD 25 million upfront payment and is eligible to receive up to USD 280 million in additional regulatory and sales milestones, plus high single-digit to low double-digit royalties on sales.

Under the terms of the transaction, ACELYRIN has obtained worldwide rights to izokibep except development and commercialization already granted to Affibody’s partner Inmagene Biopharmaceuticals Co., Ltd. in selected Asian countries. Additionally, Affibody is retaining commercialization rights in the Nordic countries.

Affibody is a clinical stage biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®. 

The Wiggin and Dana team was led by Partner Patti Melick (Picture) and Associate Madeleine Tavcar. 


Involved fees earner: Patti Melick – Wiggin & Dana-Nh ; Madeleine Tavcar – Wiggin & Dana-Nh ;

Law Firms: Wiggin & Dana-Nh ;

Clients: Affibody AB ;

Sonia Carcano

Author: Sonia Carcano